New Antibiotic May Cure and Prevent E. coli O157:H7 Infection
A new antibiotic that may cure as well as prevent infection from E. coli O157:H7 is the topic of a recent scientific study published in the journal Antimicrobial Agents and Chemotherapy. What makes this E. coli O157 antibiotic novel is that it takes advantage of a key antibacterial protein complex that some types of bacteria secrete to kill off competing bacteria. The study demonstrates that this new antibiotic delivered orally in experimental rabbits before and after bacterial exposure and infection with E. coli O157 resulted in prevention and recovery from a bacterial disease that infects approximately 73,000 people annually in the U.S.
Treating an infection from the bacterium E. coli O157 is problematical in two ways. The first way is that treatment with some antibiotics often makes the patient increasingly ill. When an antibiotic kills the bacteria, the bacteria then releases toxins that cause severe diarrhea and intestinal inflammation. Another complication is that the antibiotic may also kill off beneficial bacteria that the gut needs to maintain a healthy microbial environment.
Researchers working in collaboration with the biotech company AvidBiotics—a research facility that focuses on developing antibacterial proteins as an alternative to traditional antibiotic drugs—believe that they have found a solution to the aforementioned problems. Their solution is to take advantage of a protein complex that some strains of bacterial secrete to kill off competing bacteria within a shared environment. The protein complex is referred to as “R-type pyocins,” which basically are high molecular weight particles that have bacteria-killing abilities.
R-type pyocins are derived from a particularly nasty type of bacteria called “Pseudomonas aeruginosa” (P. aeruginosa), that according to scientists are able to infect just about anything that lives. It is a free-living, gram negative bacterium, commonly found in soil and water and is one of the few types of bacteria that are considered to be true pathogens of plants. However, P. aeruginosa is also recognized as an emerging opportunistic pathogen of humans, particularly in clinical settings as a source of antibiotic resistant, nosocomial (in hospital) infection.
P. aeruginosa causes a wide range of infections in patients with severe burns, and in cancer and AIDS patients who are immunosuppressed. The infections include urinary tract infections, respiratory system infections, bacteremia, bone and joint infections, gastrointestinal infections dermatitis, soft tissue infections and systemic infections. The fatality rate in immunocompromised patients with P. aeruginosa infection is approximately 50 percent. According to the CDC, P. aeruginosa is the fourth most common hospital infection and is responsible for about 10 percent of all nosocomial infections. However, there is a good side to P. aeruginosa. As it turns out, some strains of P. aeruginosa are deadly to other types of pathogenic bacteria.
Like humans, bacteria are also susceptible to infection by viruses. Viruses that attack bacteria are called bacteriophages. The hypothesis is that many years ago, some bacteria types were able to engulf bacteriophages and subsequently incorporate some sections of virus DNA into the bacterium’s DNA. One of the hypothesized sections of virus DNA that was incorporated by the bacteria DNA was that which made up the tail section of a virus. The tail section of a virus plays an important role in recognizing, adhering to and infecting a bacterial or human cell.